Immune Modulation in Cancer with Antibodies

Ipilimumab is the prototypical immunomodulatory antibody, approved by the FDA in 2011 for advanced melanoma on the basis of survival benefit. Since that time, we have made significant strides in optimizing this therapy: we have characterized the spectrum of immune-related adverse events and learned...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of medicine 2014-01, Vol.65 (1), p.185-202
Main Authors: Page, David B, Postow, Michael A, Callahan, Margaret K, Allison, James P, Wolchok, Jedd D
Format: Article
Language:English
Subjects:
Algorithms
anti-CTLA-4
anti-PD-1
anti-PD-L1
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
B7-H1 Antigen - antagonists & inhibitors
Biomarkers
CTLA-4 Antigen - antagonists & inhibitors
Humans
Immunologic Factors - therapeutic use
immunotherapy
Immunotherapy - methods
Ipilimumab
Medical treatment
Melanoma
Melanoma - drug therapy
Melanoma - immunology
MK-3475
Neoplasms - drug therapy
Neoplasms - immunology
nivolumab
Programmed Cell Death 1 Receptor - antagonists & inhibitors
tremelimumab
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ipilimumab is the prototypical immunomodulatory antibody, approved by the FDA in 2011 for advanced melanoma on the basis of survival benefit. Since that time, we have made significant strides in optimizing this therapy: we have characterized the spectrum of immune-related adverse events and learned how to mitigate them with treatment algorithms, discovered potential biomarkers of activity, and identified the potential synergy between checkpoint modulation and other therapeutic modalities. Recent phase I trials have established the efficacy and safety of next-generation checkpoint agents, including PD-1 and PD-L1 inhibitors, across multiple tumor types. Much work lies ahead in developing these next-generation checkpoint agents, testing them in combination, and determining how to integrate them into the treatment paradigms of various tumor types.
ISSN:0066-4219
1545-326X
DOI:10.1146/annurev-med-092012-112807